Latest News

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.

Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.

FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.

FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.

FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.

If approved, ecopipam would be the first new therapy indicated for pediatric patients with Tourette syndrome in more than 10 years.

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.